Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Intellia Therapeutics: Realizing the Dream of Curing Devastating Diseases

Intellia Therapeutics Reporting operational highlights and financial results for the second quarter ended June 30, 2020, Intellia Therapeutics ( NTLA ) announced its first Clinical Trial Application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency ( MHRA ) to...

August 11, 2020

We Introduce UroGen Pharma and Discuss Its Pipeline of Products

Presenting UroGen Pharma UroGen Pharma ( URGN ) focuses on cancers and urologic diseases. It announced its fourth quarter and full-year ended December 31, 2019 financial results. The announcement started with Liz Barrett, President and Chief Executive Officer (CEO) of UroGen...

April 2, 2020

The Time Has Come for Us To Present Fate Therapeutics

Presenting Fate Therapeutics Today we are presenting Fate Therapeutics ( FATE ); a clinical-stage company developing programmed cellular immunotherapies for cancer and immune disorders. Our enthusiasm for this firm is due to its announcement that it signed a global collaboration...

April 3, 2020

Novavax: A Hand-Picked Vaccine on the Road Towards Human Clinical Trial Against Coronavirus

Novavax Identified an "Ideal" Coronavirus Vaccine Candidate The news from Novavax ( NVAX ) informs that the firm has identified an "ideal" coronavirus vaccine candidate, NVX-CoV2373 , that is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. The...

April 8, 2020

A Royal Reception by Investors for CureVac. See Also: Good Oncology News for Bristol-Myers Squibb

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock exchange with the symbol CVAC , as of August 14, 2020. We assume you must have heard the name of this firm by now...

August 17, 2020

Moderna Encouraging News. See Also: Translate Bio and Sanofi Good News

Moderna Presented Interim Clinical Data about mRNA-1273 for COVID-19 Moderna ( MRNA ) presented new Interim Clinical Data about its mRNA Vaccine ( mRNA-1273 ) against COVID-19 at the Advisory Committee on Immunization Practices ( ACIP ) Meeting. The presentation...

August 27, 2020

Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals ( RYTM ) is a late-stage biopharmaceutical company with a product pipeline that reflects its focus of developing treatments for rare genetic obesity. The firm’s lead product, setmelanotide, is a melanocortin-4 receptor ( MC4R )...

August 28, 2020

Moderna Inc Stock is Tanking After Rallying

Moderna Inc Late August Announcements On August 28, 2020 Moderna Inc ( MRNA ) issued a press release confirming that the Company is engaged in discussions with the Ministry of Health, Labor and Welfare of Japan ( MHLW ) to...

September 1, 2020

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 1)

Halozyme and PTC Therapeutics: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed the FDA approvals are expected to tremendously boost these firms' values. Today...

April 24, 2020

Be Careful NOT to Underestimate the Following Biotech Stocks (Part 2)

Theravance Biopharma: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed we expect the FDA approvals to tremendously boost these firms’ values. I n Part...

April 26, 2020

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024